Predictive Value of Metabolic Parameters Derived From 18F-FDG PET/CT for Microsatellite Instability in Patients With Colorectal Carcinoma

被引:12
|
作者
Liu, Hao [1 ,2 ]
Ye, Zheng [1 ]
Yang, Ting [1 ]
Xie, Hongjun [2 ]
Duan, Ting [1 ]
Li, Mou [1 ]
Wu, Min [1 ]
Song, Bin [1 ]
机构
[1] Sichuan Univ, West China Hosp, Dept Radiol, Chengdu, Peoples R China
[2] Sichuan Acad Med Sci, Sichuan Prov Peoples Hosp, Dept Nucl Med, Chengdu, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2021年 / 12卷
关键词
PET; CT; metabolism; colorectal carcinoma; microsatellite instability; immunotherapy; TOTAL LESION GLYCOLYSIS; CANCER PATIENTS; TUMOR VOLUME; PROGNOSTIC VALUE; MISMATCH REPAIR; HETEROGENEITY; SURVIVAL; UTILITY;
D O I
10.3389/fimmu.2021.724464
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background Microsatellite instability (MSI) is one of the important factors that determine the effectiveness of immunotherapy in colorectal cancer (CRC) and serves as a prognostic biomarker for its clinical outcomes. Purpose To investigate whether the metabolic parameters derived from(18)F-fluorodeoxyglucose (F-18-FDG) positron emission tomography/computed tomography (PET/CT) can predict MSI status in patients with CRC. Materials and Methods A retrospective analysis was performed on CRC patients who underwent F-18-FDG PET/CT examination before surgery between January 2015 and April 2021. The metabolic F-18-FDG PET/CT parameters of the primary CRC lesion were calculated and recorded with different thresholds, including the maximum, peak, and mean standardized uptake value (SUVmax, SUVpeak, and SUVmean), as well as the metabolic tumor volume (MTV) and the total lesion glycolysis (TLG). The status of MSI was determined by immunohistochemical assessment. The difference of quantitative parameters between MSI and microsatellite stability (MSS) groups was assessed, and the receiver operating characteristic (ROC) analyses with area under ROC curves (AUC) was used to evaluate the predictive performance of metabolic parameters. Results A total of 44 patients (24 men and 20 women; mean +/- standard deviation age: 71.1 +/- 14.2 years) were included. There were 14 patients in the MSI group while there were 30 in the MSS group. MTV30%, MTV40%, MTV50%, and MTV60%, as well as TLG(50%) and TLG(60%) showed significant difference between two groups (all p-values <0.05), among which MTV50% demonstrated the highest performance in the prediction of MSI, with an AUC of 0.805 [95% confidence interval (CI): 0.657-0.909], a sensitivity of 92.9% (95% CI: 0.661-0.998), and a specificity of 66.7% (95% CI: 0.472-0.827). Patients' age and MTV50% were significant predictive indicators of MSI in multivariate logistic regression. Conclusion The metabolic parameters derived from(18)F-FDG PET/CT were able to preoperatively predict the MSI status in CRC, with MTV50% demonstrating the highest predictive performance. PET/CT imaging could serve as a noninvasive tool in the guidance of immunotherapy and individualized treatment in CRC patients.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Prognostic role of metabolic 18F-FDG PET/CT parameters and hematological prognostic indicators in patients with colorectal cancer
    Cengiz, Arzu
    Yersal, Ozlem
    Omurlu, Imran Kurt
    Yurekli, Yakup
    INDIAN JOURNAL OF CANCER, 2023, 60 (02) : 224 - 229
  • [22] Prognostic and Predictive Values of Metabolic Parameters of 18F-FDG PET/CT in Patients With Non-Small Cell Lung Cancer Treated With Chemotherapy
    Li, Xueyan
    Wang, Dawei
    Yu, Lijuan
    MOLECULAR IMAGING, 2019, 18
  • [23] Metabolic parameters on baseline 18F-FDG PET/CT are potential predictive biomarkers for immunotherapy in patients with head and neck squamous cell carcinoma
    Kwon, Hye Ryeong
    Cho, Junhun
    Park, Sehhoon
    Lee, Se-Hoon
    Ahn, Myung-Ju
    Choi, Joon Young
    Lee, Kyung-Han
    Jung, Hyun Ae
    Moon, Seung Hwan
    FRONTIERS IN MEDICINE, 2022, 9
  • [24] Predictive Value of 18F-FDG PET/CT for Vascular Invasion in Patients With Hepatocellular Carcinoma Before Liver Transplantation
    Lin, Chun-Yi
    Liao, Chiung-Wei
    Chu, Lu-Yen
    Yen, Kuo-Yang
    Jeng, Long-Bin
    Hsu, Cheng-Nan
    Lin, Cheng-Li
    Kao, Chia-Hung
    CLINICAL NUCLEAR MEDICINE, 2017, 42 (04) : E183 - E187
  • [25] Prognostic Value of 18F-FDG PET/CT Metabolic Parameters in Metastatic Differentiated Thyroid Cancers
    Masson-Deshayes, Soizic
    Schvartz, Claire
    Dalban, Cecile
    Guendouzen, Sofiane
    Pochart, Jean-Marie
    Dalac, Audrey
    Fieffe, Sandrine
    Bruna-Muraille, Claire
    Dabakuyo-Yonli, Tienhan Sandrine
    Papathanassiou, Dimitri
    CLINICAL NUCLEAR MEDICINE, 2015, 40 (06) : 469 - 475
  • [26] Prognostic value of 18F-FDG PET/CT metabolic parameters in patients with locally advanced pancreatic Cancer treated with stereotactic body radiation therapy
    Ren, Shengnan
    Zhu, Xiaofei
    Zhang, Anyu
    Li, Danni
    Zuo, Changjing
    Zhang, Huojun
    CANCER IMAGING, 2020, 20 (01)
  • [27] Preoperative risk stratification using metabolic parameters of 18F-FDG PET/CT in patients with endometrial cancer
    Kitajima, Kazuhiro
    Suenaga, Yuko
    Ueno, Yoshiko
    Maeda, Tetsuo
    Ebina, Yasuhiko
    Yamada, Hideto
    Okunaga, Takashi
    Kubo, Kazuhiro
    Sofue, Keitarou
    Kanda, Tomonori
    Tamaki, Yukihisa
    Sugimura, Kazuro
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 (08) : 1268 - 1275
  • [28] Predictive value of intratumor metabolic and heterogeneity parameters on [18F]FDG PET/CT for EGFR mutations in patients with lung adenocarcinoma
    Ni, Ming
    Wang, Shicun
    Liu, Xin
    Shi, Qin
    Zhu, Xingxing
    Zhang, Yifan
    Xie, Qiang
    Lv, Weifu
    JAPANESE JOURNAL OF RADIOLOGY, 2023, 41 (02) : 209 - 218
  • [29] Clinical significance of 18F-FDG PET/CT in colorectal carcinoma
    Nemeth Zsuzsanna
    Boer Katalin
    Kasler Miklos
    Borbely Katalin
    ORVOSI HETILAP, 2013, 154 (37) : 1447 - 1453
  • [30] 18F-FDG PET/CT evaluation of patients with ovarian carcinoma
    Iagaru, Andrei H.
    Mittra, Erik S.
    McDougall, Iain Ross
    Quon, Andrew
    Gambhir, Sanjiv Sam
    NUCLEAR MEDICINE COMMUNICATIONS, 2008, 29 (12) : 1046 - 1051